Literature DB >> 20885315

Choice of initial medical therapy vs. prompt coronary revascularization in patients with type 2 diabetes and stable ischemic coronary disease with special emphasis on the BARI 2D trial results.

Bernard R Chaitman1, Mazen Hadid, Abhay A Laddu.   

Abstract

PURPOSE OF REVIEW: To determine whether a strategy of prompt coronary revascularization as compared with an initial strategy of intensive optimal medical therapy (OMT) in patients with type 2 diabetes and stable coronary artery disease (CAD) prevents major adverse cardiac outcomes. RECENT
FINDINGS: Randomized controlled clinical trials comparing a strategy of prompt coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI) or medical therapy in patients with type 2 diabetes are reviewed with special emphasis on the Bypass Angioplasty Revascularization Investigation 2D trial. An initial strategy of PCI or CABG alleviates symptoms and improves quality of life more than an initial strategy of OMT. However, an initial strategy of PCI in patients with less extensive CAD does not significantly reduce death or myocardial infarction. Patients with more extensive CAD in whom a more complete coronary revascularization can be achieved with CABG have less subsequent myocardial infarction, a complication associated with increased mortality, than those treated with initial OMT.
SUMMARY: In many patients with type 2 diabetes and stable CAD in whom angina symptoms are controlled, OMT alone should be the first-line strategy. In patients with more extensive coronary disease, prompt CABG, in the absence of contraindications, OMT, and an insulin sensitization strategy are a preferred therapeutic strategy to reduce the incidence of myocardial infarction.

Entities:  

Mesh:

Year:  2010        PMID: 20885315     DOI: 10.1097/HCO.0b013e32833f0461

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  3 in total

Review 1.  Revascularization for left main and multivessel coronary artery disease in the drug-eluting stent era: integration of recent drug-eluting stent trials.

Authors:  Samip Vasaiwala; David O Williams
Journal:  Curr Cardiol Rep       Date:  2012-08       Impact factor: 2.931

Review 2.  Stable angina pectoris: antianginal therapies and future directions.

Authors:  Bernard R Chaitman; Abhay A Laddu
Journal:  Nat Rev Cardiol       Date:  2011-08-30       Impact factor: 32.419

Review 3.  Antagonist molecules in the treatment of angina.

Authors:  Ashish K Gupta; David Winchester; Carl J Pepine
Journal:  Expert Opin Pharmacother       Date:  2013-09-18       Impact factor: 3.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.